Yes, Obijankenobi, I find the straightforward sty

Yes, Obijankenobi,

I find the straightforward style of that paragraph very indicative of the probably decisive importance of Kevetrin to the future of treating various kinds of cancer:

"Cancer treatment may get customizable. We may be getting closer than ever to winning the war on cancer, because researchers have come up with a single drug that can treat many different kinds of cancers, such as melanoma, breast cancer, and leukemia. Drugs such as Kevetrin, now in Phase I clinical trials at Harvard University’s Dana-Farber Cancer Institute, work with the body’s natural defense system to target what’s known as the “guardian angel gene” (a.k.a. the p53 protein) to program it to either fix a cancerous cell or make it to self-destruct. If FDA-approved, this customizable cancer drug could especially benefit those with rare types of the disease that don’t get much funding."

**************

The message couldn't come through much stronger than that. Just looking at another prominent biotech that had news yesterday, In Vivo (NVIV), any material event is likely to produce a quick response in the SP. My guiding principle in this case is that it's more a matter of "when", rather than a matter of "if", because all the preliminary indications with Kevetrin (and with Prurisol, too) have reinforced expectations. Naturally, definitive news is what we are waiting for, and that too will come step by step, but we are getting closer.